Rebalancing agents represent a novel therapeutic class in haemophilia, designed to restore the deficient thrombin generation that underlies bleeding. Unlike factor replacement or factor VIII mimetic therapies, rebalancing agents act by downregulating natural anticoagulants.
By partially inhibiting these physiological brakes of coagulation, they induce a controlled and reversible procoagulant shift. These agents have shown clinically meaningful reductions in bleeding rates across both haemophilia A and B, including in patients with inhibitors.
The Lancet Haematology published a clinical update in Oncology on 10 Mar 2026.
The item focuses on Balancing the benefits and risks of rebalancing coagulation in haemophilia.
Review the original article for the full source wording and details.